Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113021 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL20743365 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL1752698 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL26496284 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL14714348 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL28115449 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL344684 | 1.00 | USP2 (0.69) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL27710759 | 0.98 | USP2 (0.66) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL4248977 | 0.92 | USP2 (0.57) | USP2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL4384489 | 0.90 | DGKA (0.58) | USP2MEN1KMT2ALMNADGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4518614-A | GIBBERELLIC ACID, LYSINE, SKIN SOFTENER | REDKEN LABORATORIES, INC. (US) | 1985-05-21 | — | — | US | claimed |
| EP-0126138-A1 | COSMETIC PREPARATION | REDKEN LABORATORIES INC. (US) | 1984-11-28 | — | — | EP | claimed |
| WO-1984001710-A1 | COSMETIC PREPARATION | REDKEN LABORATORIES INC (US) | 1984-05-10 | — | — | WO | claimed |
| CN-111848368-A | Method for improving purity of batyl alcohol in shark liver oil | 浙江工商大学 | 2020-10-30 | — | — | CN | disclosed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| EP-2125838-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD (IL) | 2016-05-11 | — | — | EP | disclosed |
| EP-2604614-B1 | Oxidized phospholipids | VASCULAR BIOGENICS LTD (IL) | 2016-03-09 | — | — | EP | disclosed |
| CN-102040621-B | Lipid oxide and the application in treatment inflammatory diseases thereof | CANALIS-HAEMALIS BIOGROWTH LTD. (IL) | 2016-01-20 | — | — | CN | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | disclosed |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| US-6838452-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-01-04 | — | — | US | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2004-06-03 | — | — | US | disclosed |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. | 2003-12-04 | — | — | US | disclosed |
| EP-1341543-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | Vascular Biogenics Ltd. (IL) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002041827-A9 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD (IL) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002041827-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885MEN1 3163/4885KMT2A 2467/4885 |
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | USP2 4148/4885MEN1 3857/4885KMT2A 4728/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | USP2 4148/4885MEN1 3857/4885KMT2A 4728/4885 |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885MEN1 3163/4885KMT2A 2467/4885 |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885MEN1 3163/4885KMT2A 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.